...and Japan, but Lundbeck has co-promotion rights in both territories. The Takeda deal also includes Lu AA24530...

...from a double-blind Phase II trial in 652 patients showed 5, 10 and 20 mg Lu AA24530...
...were low and similar to duloxetine. The company granted Takeda rights to co-develop and co-commercialize Lu AA24530...
...2007). H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Lu AA24530...

...a Phase II trial to treat major depressive disorder showed 5, 10 and 20 mg Lu AA24530...

...GAD) Ph III Nalmefene [BioTie (HSE:BTH1V)/ Somaxon (NASDAQ:SOMX)] Opioid receptor antagonist Alcohol dependence Ph III Lu AA24530...

...atypical antipsychotic Psychosis Ph II Lu AA21004 Serotonin modulator and stimulator Depression Ph II Takeda Lu AA24530...

...family are Lu AA21004 , which is to enter Phase III testing this quarter, and Lu AA24530...
...agreement with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan). The deal covers Lu AA21004 and Lu AA24530...
...trial this quarter. Also, in October, the partners started a 600-patient Phase II trial of Lu AA24530...

...10). H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Lu AA24530...

...serotonin modulator and stimulator, is in Phase II testing to treat major depressive disorder (MDD). Lu AA24530...

...modulator and stimulator, is in Phase II testing to treat major depressive disorder (MDD), and Lu AA24530...

...a Phase I trial for Lu AA 24530. H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Product: Lu AA24530...